Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.09.19.558346

Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis in rabbit

Oguri, N.·Gi, T.·Nakamura, E.·Maekawa, K.·Furukoji, E.·Okawa, H.·Sho, K.·Horiuchi, S.·Sakae, T.·Azuma, M.·Asada, Y.·Yamashita, A.
View original source ↗Export metadata ↓

Abstract

BackgroundNovel anticoagulants targeting coagulation factor XI (FXI)/activated FXI (FXIa) are under development. However, whether FXI is present in human deep vein thrombosis (DVT) and whether FXIa and activated factor X (FXa) play different roles in venous thrombus formation and hemostasis remain unclear. This study aimed to determine the presence of FXI in DVT and the effects of direct oral FXIa and FXa inhibitors on venous thrombus formation and hemostasis in rabbits and mural thrombus formation in flow chamber system. MethodsWe immunohistochemically assessed FXI localization in human aspirated DVT (n=15). Additionally, we compared thrombus formation induced by endothelial denudation and stenosis in jugular vein, and skin bleeding time and volume between rabbits treated with direct FXIa inhibitors (ONO-1600586) and FXa inhibitors (rivaroxaban). Ex vivo rabbit and human blood were perfused on a flow chamber under low shear rates (70/s). ResultFXI was localized in all DVT, predominantly in fibrin-rich areas. The FXI-immunopositive area in the non-organizing area was greater than that in the organizing area. Although FXIa and FXa inhibitors comparably inhibited venous thrombus formation, FXIa inhibitors did not affect bleeding time or volume in rabbits. FXIa or FXa inhibitors mildly or strongly inhibited fibrin formation at low shear rates respectively. Furthermore, the FXIa inhibitor suppressed human FXIa activity, thrombin generation, and fibrin formation during perfusion. ConclusionThe pathological findings of human DVT suggest FXIs role in human DVT. FXIa inhibitors may inhibit less fibrin formation than FXa inhibitors, and may explain the minor role of FXIa in hemostasis. EssentialO_LIPresence of factor XI (FXI) in venous thrombus and less bleeding in its inhibition are unclear. C_LIO_LIWe assessed FXI localization in deep vein thrombosis (DVT) and function of FXIa in rabbit. C_LIO_LIFXI localized in human DVT that provide a rationale for FXI inhibition in human DVT. C_LIO_LIFXIa inhibitor inhibited less fibrin formation than factor Xa inhibitor under low-shear rate. C_LI

Source connections

Explore related subjects

pathologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Oguri, N., Gi, T., Nakamura, E., Maekawa, K., Furukoji, E., Okawa, H., Sho, K., Horiuchi, S., Sakae, T., Azuma, M., Asada, Y., Yamashita, A.. 2023-09-22. Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis in rabbit. https://doi.org/10.1101/2023.09.19.558346

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗
bioRxiv2026

Relative expression of THY1 and PDGFRA in equine endometrosis in relation to severity, histopathological features and endometrial transcripts

Equine endometrosis is a degenerative uterine disease characterized by periglandular fibrosis and represents a major cause of subfertility in mares. While stromal cell activation results in pathological tissue remodeling, the involvement of cell-surface integrators (THY1) and growth factor receptors (PDGFRA) was not researched. This study evaluated the relative mRNA expression of THY1 and PDGFRA across Kenney and Doig (KD) endometrosis categories and specific histopathological features. Additionally, transcriptomic correlation profiles between target genes and markers of myofibroblast differentiation (ACTA2), cellular proliferation (MKI67), and steroid hormone receptors (ESR1, PGR) were analyzed. Endometrial samples (n = 47) were quantified using RT-qPCR. Relative mRNA expression of THY1 differed significantly across KD categories (p = 0.014), exhibiting a transient upregulation in category IIA compared with category I (p = 0.009) and category IIB (p = 0.002). Furthermore, THY1 relative mRNA expression was significantly elevated in tissues with glandular basal lamina disruption (p = 0.022). Conversely, PDGFRA relative mRNA expression remained stable across disease categories (p > 0.05). THY1 relative mRNA expression correlated very strongly with ACTA2 ({rho} = 0.875, p < 0.001) and strongly with ESR1 ({rho} = 0.652, p < 0.001). PDGFRA relative mRNA expression exhibited a very strong positive correlation with ESR1 ({rho} = 0.864, p < 0.001) and a strong positive correlation with MKI67 ({rho} = 0.674, p < 0.001). These results indicate that THY1 transcription is transiently induced during early stromal remodeling and basal lamina loss, whereas PDGFRA maintains constitutive transcript stability. Observed co-expression profiles reflect statistical co-variation among stromal remodeling, proliferative, and steroid-responsive cell populations in bulk tissue.

pathology↗
bioRxiv2026

CD8+ T-cells protect against experimental atherosclerosis through antigen specific interactions in the plaque

Atherosclerosis is a chronic inflammatory disease with a significant adaptive immune component. CD8+ T cells accumulate in plaques and display signatures of antigen-specific activation. However, whether this accumulation is driven by local antigen recognition and what functional consequences follow, remains poorly understood. Here we address this gap of knowledge using loss- and gain-of-function experiments. Atherosclerotic Rag-/-Ldlr-/- mice received adoptively transferred wildtype or antigen-restricted CD8+ T cells alongside CD4+ T cells to distinguish antigen-specific from antigen-independent responses. In a complementary model, ApobOVA-TGxLdlr-/- mice, expressing an ovalbumin-tagged variant of the atherosclerosis-associated ApoB100 protein, enabled OT-I CD8+ T cells to function as atherosclerosis-antigen-specific CD8+ T cells. T-cell distribution, activation and phenotype were assessed systemically and within lesions, plaque burden and composition were quantified histologically. Wildtype CD8+ T cells accumulated significantly more in aortic lesions compared to antigen-restricted CD8+ T cells, and exhibited increased activation, exhaustion and cytokine secretion, indicating that plaque-infiltrating T cells are predominantly antigen-specific. Perturbing antigen-specific CD8+ T-cell interactions significantly decreased plaque stability index, suggesting a protective role for antigen-specific CD8+ T cells. In ApobOVA-TGxLdlr-/- mice, OT-I T cells accumulated at high frequency in the liver, consistent with hepatic ApoB100-expression, and were found in circulation and aorta. Histological analysis revealed reduced plaque burden in OT-I recipients, reproducing an atheroprotective effect of antigen-specific CD8+ T-cell responses. Plaque reduction coincided with reduced TUNEL, but similar Caspase 3 staining, suggesting OT-I transfer results in reduced secondary necrosis. In line with this, CD47 expression in OT-I recipient mice was reduced and in vitro, OT-I but not antigen non-specific CD8+ T cells reduced expression of CD47 on OVA-presenting foam cells. CD8+ T-cell accumulation in experimental atherosclerosis is driven primarily by antigen-specific interactions and such responses are associated with plaque stabilization and reduced lesion formation, potentially through induction of apoptosis and prevention of secondary necrosis

pathology↗